Table 5.
Effect of increased inclusions of a Saccharomyces cerevisiae fermentation product (SCFP) on serum lysozyme and Bovine Viral Diarrhea Virus Type 1 (BVDABT1) and 2 (BVDABT2) antibody titers of newly weaned beef steers during a 56-d receiving period
| Treatment1 | P-value | |||||
|---|---|---|---|---|---|---|
| CON | SCFP14 | SCFP28 | SEM2 | Linear | Quadratic | |
| Serum | ||||||
| Lysozyme, U/mL3 | ||||||
| Day 0 | 47.0 | 26.1 | 42.5 | – | – | – |
| Day 27 | 43.0 | 39.2 | 39.2 | 4.68 | 0.57 | 0.75 |
| Day 56 | 32.2 | 36.1 | 38.9 | 2.87 | 0.11 | 0.88 |
| BVDABT13,4 | 2.51 | 2.45 | 2.14 | 0.219 | 0.23 | 0.65 |
| BVDABT23,4 | 1.65 | 1.72 | 1.69 | 0.187 | 0.88 | 0.82 |
1CON = Original XPC (Diamond V, Cedar Rapids, IA) at 0 g·steer−1·d−1; SCFP14 = Original XPC at 14 g·steer−1·d−1; SCFP28 = Original XPC at 28 g·steer−1·d−1.
2Highest SEM of any treatment is reported.
3Day 0 values used as a covariate in analysis.
4Log transformed (log10); based on repeated measures analysis, treatment × day P ≥ 0.16 for all variables.